Recent Updates
Recently added Catalysts
TARS Positive Sentiment Score: 65/100

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Thursday, February 20, 2025 1 min read
Key Takeaway: Tarsus Pharmaceuticals, Inc. will report its fourth quarter and full-year 2024 financial results during a live webcast on February 25, 2025. The event will start at 5:00 a.m. PT / 8:00 a.m. ET, and a recorded version will be available afterward. The company continues to focus on revolutionizing treatment in eye care and infectious disease prevention, with an advancing pipeline including therapies for Ocular Rosacea and Lyme disease prevention.

Market Sentiment Analysis

POSITIVE FACTORS

  • Tarsus Pharmaceuticals is set to report its financial results, indicating ongoing corporate operations.
  • The company is advancing its pipeline with promising therapies targeting diseases of high unmet need.
  • Tarsus has FDA approval for XDEMVY, demonstrating credibility in treatment development.

Full Press Release Details

IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.
Sr. Director, Corporate Communications
Head of Investor Relations
DNakasone@tarsusrx.com

Frequently Asked Questions

When is Tarsus Pharmaceuticals' live webcast?

The live webcast is scheduled for February 25, 2025, at 5:00 a.m. PT.

Where can I access the Tarsus webcast?

Participants can access the webcast through the link provided by Tarsus Pharmaceuticals.

What does Tarsus Pharmaceuticals focus on?

Tarsus Pharmaceuticals focuses on revolutionizing treatments, particularly in eye care.

What is XDEMVY® used for?

XDEMVY® is FDA-approved for treating Demodex blepharitis.

What are TP-04 and TP-05 being developed for?

TP-04 targets Ocular Rosacea, while TP-05 aims to prevent Lyme disease.

Tags: TARS Viatris Investor Conferences Healthcare Tarsus Pharmaceuticals XDEMVY Ocular Rosacea Lyme disease prevention
Last updated: Feb 20, 2025